Importantly, we revealed that KDM6A knockdown significantly reduced the sensitivity of HCC cells to lenvatinib treatment by regulating FGFR4 expression, indicating that patients suffering from HCC with a low KDM6A expression may be more resistant to lenvatinib‐targeted therapy. The gene discussed is FGFR4; the disease is hepatocellular carcinoma.